The international team of researchers showed that the transfusion of the blood plaza of the blood underwent coronavirus infection does not help in the treatment of critical patients with COVID-19. Article of scientists has been published in Journal of the American Medical Association.
More than two thousand people with severe coronavirus infection took part in a clinical study of the efficiency of the common method of treating COVID-19. For three weeks, scientists observed whether the participants of the experimental will survive – received two donor plasma units – and control groups without the need for artificial ventilation of the lungs.
The study was stopped after the team with a probability of 99 percent found that the blood plasma of the victims does not benefit critical patients. The mortality rate in the experimental group was 37 percent, in the control – 38. The reason for this scientist could not be established. “We assume that this can be a combination of too low in the plasma of high-quality antibodies and too much progress in patients”, – notes one of the leading authors of the study of Derek Angus.
At the same time, this treatment method has improved the state of 126 patients with weakened immunity – however, the researchers indicate, the sample is too small in order to come to any conclusions.
Earlier in the British Medical Journal, a study was published, according to which the plasma recovered from Coronavirus was useless in the treatment of new fallen.